Express Pharma

BioNTech to lead $2 bn mRNA-based oncology therapy market despite challenges: GlobalData

BioNTech's diverse pipeline includes multiple drugs in Phase I, II, and III clinical trials, predominantly targeting solid tumors such as melanoma, prostate cancer, cervical cancer, non-small cell lung cancer, and pancreatic cancer

0 351